---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-122156"
form_type: "8-K"
ticker: "PRME"
cik: "0001894562"
company_name: "Prime Medicine, Inc."
filed_at: "2025-05-19T23:59:59+00:00"
generated_at: "2026-05-21T02:11:21.087654+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# Prime Medicine CEO Gottesdiener resigns; Reine named CEO; positive CGD data; restructures to liver focus

## Summary
- Keith Gottesdiener resigned as CEO and board member; CFO Allan Reine appointed CEO and to board, effective May 19, 2025.
- Jeff Marrazzo named Executive Chair of the board.
- First clinical data for PM359 in CGD: 58% DHR positivity at Day15, 66% at Day30, well above 20% threshold; rapid engraftment.
- Company to deprioritize CGD programs, seek partner for PM359; focus on Wilson's Disease and AATD with IND/CTA in 1H2026 and mid-2026.
- Workforce reduction and cost cutting to reduce cash needs; Beam arbitration ongoing.

## SEC filing metadata
- accession: 0001193125-25-122156
- form_type: 8-K
- ticker: PRME
- cik: 0001894562
- company_name: Prime Medicine, Inc.
- filed_at: 2025-05-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1894562/000119312525122156/0001193125-25-122156-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1894562/000119312525122156/d863812d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-122156
- JSON: https://secwatch.observer/filing/0001193125-25-122156.json
- Plain text: https://secwatch.observer/filing/0001193125-25-122156.txt

## Key facts
- Executive change
  Allan Reine was appointed as member of the Board of Directors at Prime Medicine, Inc..
  - Action: appointed
  - Role: member of the Board of Directors
  source text: The Board also appointed Dr. Reine to serve as a member of the Board as a Class II director
  evidence_url: https://www.sec.gov/Archives/edgar/data/1894562/000119312525122156/0001193125-25-122156-index.htm
- Executive change
  Keith Gottesdiener resigned as President, Chief Executive Officer and principal executive officer at Prime Medicine, Inc..
  - Action: resigned
  - Role: President, Chief Executive Officer and principal executive officer
  source text: Keith Gottesdiener, M.D. had resigned as President, Chief Executive Officer and principal executive officer of the Company, and as a member of the Board of Directors of the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/1894562/000119312525122156/0001193125-25-122156-index.htm
- Executive change
  Allan Reine was appointed as Chief Executive Officer and principal executive officer at Prime Medicine, Inc..
  - Action: appointed
  - Role: Chief Executive Officer and principal executive officer
  source text: the Board appointed Allan Reine, M.D., the Company’s Chief Financial Officer and principal financial officer, as Chief Executive Officer and principal executive officer of the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/1894562/000119312525122156/0001193125-25-122156-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.